Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical ...

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in child ...

Arcutis aims to expand its market reach with new approvals. Management recently pleased the market with its sales guidance ...

With all that in mind, if you have $2,000 available to invest that isn't needed for monthly bills, to pay down short-term ...

Any practitioner who cares for patients with psoriasis should be familiar with and make use of systemic therapies. These medications are clearly indicated for patients who have diffuse disease where ...

ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remissionOver $500M cash ...

Medicare Part B premiums are jumping 12% in 2026. Learn about new costs, Advantage plan cuts, and the enrollment deadline ...

ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three ...

These companies have exceptional dividend track records. AbbVie is moving on from its Humira patent losses, and its portfolio ...

The S&P 1500 Health Care Index gained 1.9% in September, underperforming the S&P 500, which advanced 3.7%. Read more here.

Bristol-Myers Squibb stands out in Big Pharma with strong sales growth and a solid dividend yield. Click here to read an ...

You've disabled cookies in your web browser. A third-party browser plugin, such as Ghostery or NoScript, is preventing ...